Dr Ramanan said adalimumab - which is currently licensed for over-13s - has already been shown to help control inflammation of the joints in children with arthritis.
Clare Smith, nine, of Portishead, North Somerset, was given adalimumab to treat her arthritis when other drugs failed to alleviate inflammation in her eyes as well as her joints.
In March this year, NICE said adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade) could only be used in the context of research, even for those patients who had failed on one anti-TNF.